Probleme bei der Darstellung von ARIVA.DE?

  • Laden unsere Charts bei Ihnen nicht?
  • Wird unser Forum bei Ihnen nicht korrekt dargestellt?

Sie nutzen einen Adblocker, der hierfür verantwortlich ist. Hierauf hat ARIVA.DE leider keinen Einfluss. Bitte heben Sie die Blockierung von ARIVA.DE in Ihrem Adblocker auf.

Probleme bei der Darstellung von ARIVA.DE?

Top-Thema

14:20 Uhr
ROUNDUP/EZB greift durch: Insolvenz für zwei italienische Krisenbanken

Karolinska Development portfolio company OssDsign announces new European partnerships for commercialization of novel medical implants

Donnerstag, 12.01.2017 08:00

STOCKHOLM - January 12, 2017 Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that portfolio company OssDsign AB, a Swedish designer, manufacturer and distributor of next generation implants for cranial and facial reconstruction, has entered new commercial partnerships covering distribution of its products in Italy, Spain, Switzerland, Austria and The Netherlands.

Details from the OssDsign announcement follow:

 

OssDsign's lead products - OSSDSIGN® Cranial and OSSDSIGN® Facial - are already on sale in Germany, the UK and the Nordic region, as well as selected non-European markets including Singapore and Israel. The Company is preparing for its first product launch in the US, which is anticipated during the first quarter of 2017, and is also undertaking regulatory and commercial activities in Japan.

 

OssDsign commercial strategy is focused on building sales of its innovative products through a combination of internal sales organisation and distribution partnerships.

 

Anders Lundqvist, CEO of OssDsign, said: "We are very pleased to increase our commercial footprint in Europe as we work to become the leading provider of regenerative implants for cranial and facial reconstruction. We now have experienced and well-motivated teams in place in order to execute our European strategy and bring OssDsign products closer to the surgeons and patients who will ultimately benefit from them."

 

Viktor Drvota, Chief Investment Officer at Karolinska Development, said: "These partnerships are positive news for OssDsign, as the Company continues to execute its commercial strategy and drive sales of its innovative product around the world."

 

For further information, please contact:

Jim Van heusden, CEO, Karolinska Development AB

Phone: +46 72 858 32 09, e-mail: jim.van.heusden@karolinskadevelopment.com

Christian Tange, CFO, Karolinska Development AB

Phone: +46 73 712 14 30, e-mail: christian.tange@karolinskadevelopment.com

David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson

Phone: +44 20 7638 9571; e-mail: KDev@citigatedr.co.uk

 

TO THE EDITORS

About OssDsign AB


OssDsign is a Swedish medtech company dedicated to creating regenerative implants for improved healing of bone defects and deficits in skull, facial and other types of surgery. OssDsign has successfully launched its first patient specific products OSSDSIGN® Cranial and OSSDSIGN® Facial in Germany, the UK and the Nordic countries, and further global market expansion is ongoing.


By combining clinical insight with proprietary material technology and patient adapted design, OssDsign supplies an expanding range of tailored solutions for cranial repair and facial bone reconstruction. OssDsign's technology is the result of collaboration between clinical researchers at the Karolinska University Hospital, Stockholm, and material science experts at the Ångström Laboratory at Uppsala University. Main investors in OssDsign are Karolinska Development, SEB Venture Capital, Fouriertransform and Almi Invest. For more information visit www.ossdsign.com

 

 

About Karolinska Development AB
Karolinska Development AB is an investment company focused on identifying medical innovation and investing in the creation and growth of companies developing these assets into differentiated products that will make a difference to patients' lives and provide an attractive return on investment.

 

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

 

Karolinska Development has established a portfolio of 12 companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

 

The Company is led by a team including investment professionals with strong venture capital backgrounds, experienced company builders and entrepreneurs, with access to a strong global network. For more information, please visit www.karolinskadevelopment.com


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire